Compare Adaptive Biotechnologies Corp (ADPT) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dominion Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while Dominion Energy Inc trades at $69.81 (market cap $60.92B). The key difference: Dominion Energy Inc is far larger — about 18.3× Adaptive Biotechnologies Corp's market cap, and Dominion Energy Inc pays a 3.86% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | D | |
|---|---|---|
Market Cap | $3.33B | $60.92B |
Sector | Health | Utilities |
52-Week High | $22.37 | $69.84 |
52-Week Low | $10.24 | $56.32 |
Enterprise Value | $3.19B | $113.32B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dominion Energy (D) trades at $69.84, up 0.13% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 16.93% net income margin and trades near the analyst consensus price target of $69.50. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning Dominion as a key player in AI infrastructure and data center power demand.
The outlook remains positive due to strategic positioning in renewable energy and data center growth, though regulatory approval risks for the merger and high debt levels pose challenges. Earnings momentum and institutional support provide upside potential, but investors should monitor merger developments and interest rate impacts on utility valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
